
## Claims

[Claim 1] A pharmaceutical composition for preventing or treating thrombogenesis-related diseases comprising clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient.

[Formula 1]




[Claim 2] The pharmaceutical composition according to claim 1, wherein a content of clopidogrel or pharmaceutically acceptable salts thereof is 10 to 300 mg.

[Claim 3] The pharmaceutical composition according to claim 1, wherein a content of the compound of Formula 1 or pharmaceutically acceptable salts thereof is 10 to 200 mg.

[Claim 4] The pharmaceutical composition according to claim 1, wherein the composition is a combination or a complex preparation.

[Claim 5] The pharmaceutical composition according to claim 1, wherein the composition is a preparation for oral administration.

[Claim 6] The pharmaceutical composition according to claim 5, wherein the preparation for oral administration is granule preparations, pellet preparations, tablets or capsule preparations.

[Claim 7] The pharmaceutical composition according to claim 1, wherein the

composition further comprising pharmaceutically acceptable additives.

[Claim 8] The pharmaceutical composition according to claim 1, wherein the composition further comprising one or more additives selected from the group consisting of diluents, disintegrants, binders, pH adjusting agents, glidants and coating agents.

[Claim 9] The pharmaceutical composition according to claim 8, wherein the diluents are one or more selected from the group consisting of microcrystalline cellulose, starch, dextrin, lactose, sucrose, mannitol, xylitol, isomalt and sorbitol.

[Claim 10] The pharmaceutical composition according to claim 8, wherein the disintegrants are one or more selected from the group consisting of sodium starch glycolate, sodium croscarmellose, hydroxypropyl cellulose, carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, maize starch or pre-gelatinized starch.

[Claim 11] The pharmaceutical composition according to claim 8, wherein the binders and coating agents are one or a combination of two or more selected from the group consisting of sodium carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone, xanthan gum, sodium alginate and gelatin.

[Claim 12] The pharmaceutical composition according to claim 8, wherein the pH adjusting agents are organic acid.

[Claim 13] The pharmaceutical composition according to claim 12, wherein the organic acid is one or more selected from the group consisting of citric acid, tartaric acid, fumaric acid, lactic acid, phosphoric acid and malic acid.

[Claim 14] The pharmaceutical composition according to claim 6, wherein the capsule preparation is filled with granules or pellets comprising clopidogrel or pharmaceutically acceptable salts thereof.

[Claim 15] The pharmaceutical composition according to claim 6, wherein the capsule preparation is filled with granules or pellets comprising a compound of Formula 1 or pharmaceutically acceptable salts thereof.

[Claim 16] The pharmaceutical composition according to claim 6, wherein the capsule preparation is filled with multi-layer coated pellets having one of clopidogrel or pharmaceutically acceptable salts thereof; or a compound of Formula 1 or pharmaceutically acceptable salts thereof in an inner layer thereof.


[Claim 17] The pharmaceutical composition according to claim 4, wherein the complex preparation does not have clopidogrel or pharmaceutically acceptable salts thereof and a compound of Formula 1 or pharmaceutically acceptable salts thereof brought into direct contact with each other.

[Claim 18] The pharmaceutical composition according to claim 4, wherein the combination is a kit type.

[Claim 19] The pharmaceutical composition according to claim 1, wherein the composition is for an antiplatelet therapy.


~~[Claim 20] A method for preventing or treating thrombogenesis-related diseases, comprising a step of administering a pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient into subjects in need.~~

~~[Formula 1]~~





~~[Claim 21] Use of clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof for preventing or treating thrombogenesis-related diseases.~~

~~[Formula 1]~~




[Claim ~~22~~20] Use of clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof in preparation of a medicament for preventing or treating thrombogenesis-related diseases.

[Formula 1]




[Claim 21] The use according to claim 20, wherein a content of clopidogrel or pharmaceutically acceptable salts thereof is 10 to 300 mg.

[Claim 22] The use according to claim 20, wherein a content of the compound of Formula 1 or pharmaceutically acceptable salts thereof is 10 to 200 mg.

[Claim 23] The use according to claim 20, wherein Clopidogrel or pharmaceutically acceptable salts thereof; and the compound of Formula 1 or pharmaceutically acceptable salts thereof are prepared into a combination or a complex preparation.

[Claim 24] The use according to claim 20, wherein Clopidogrel or pharmaceutically acceptable salts thereof; and the compound of Formula 1 or pharmaceutically acceptable salts thereof are prepared into a preparation for oral administration.

[Claim 25] The use according to claim 24, wherein the preparation for oral administration is granule preparations, pellet preparations, tablets or capsule preparations.

[Claim 26] The use according to claim 20, wherein Clopidogrel or pharmaceutically acceptable salts thereof; and the compound of Formula 1 or pharmaceutically acceptable salts thereof are further combined with pharmaceutically acceptable additives.

[Claim 27] The use according to claim 20, wherein Clopidogrel or pharmaceutically acceptable salts thereof; and the compound of Formula 1 or pharmaceutically acceptable salts thereof are further combined with one or more additives selected from the group consisting of diluents, disintegrants, binders, pH adjusting agents, glidants and coating agents.

[Claim 28] The use according to claim 27, wherein the diluents are one or more selected from the group consisting of microcrystalline cellulose, starch, dextrin, lactose, sucrose, mannitol, xylitol, isomalt and sorbitol.

[Claim 29] The use according to claim 27, wherein the disintegrants are one or more selected from the group consisting of sodium starch glycolate, sodium croscarmellose, hydroxypropyl cellulose, carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, maize starch or pre-gelatinized starch.

[Claim 30] The use according to claim 27, wherein the binders and coating agents are one or a combination of two or more selected from the group consisting of sodium carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone, xanthan gum, sodium alginate and gelatin.

[Claim 31] The use according to claim 27, wherein the pH adjusting agents are organic acid.

[Claim 32] The use according to claim 31, wherein the organic acid is one or more selected from the group consisting of citric acid, tartaric acid, fumaric acid, lactic acid, phosphoric acid and malic acid.

[Claim 33] The use according to claim 25, wherein the capsule preparation is filled with granules or pellets comprising clopidogrel or pharmaceutically acceptable salts thereof.

[Claim 34] The use according to claim 25, wherein the capsule preparation is filled with granules or pellets comprising a compound of Formula 1 or pharmaceutically acceptable salts thereof.

[Claim 35] The use according to claim 25, wherein the capsule preparation is filled with multi-layer coated pellets having one of clopidogrel or pharmaceutically acceptable salts thereof; or a compound of Formula 1 or pharmaceutically acceptable salts thereof in an inner layer thereof.

[Claim 36] The use according to claim 23, wherein the complex preparation does not have clopidogrel or pharmaceutically acceptable salts thereof and a compound of Formula 1 or pharmaceutically acceptable salts thereof brought into direct contact with each other.

[Claim 37] The use according to claim 23, wherein the combination is a kit type.

[Claim 38] The use according to claim 20, wherein Clopidogrel or pharmaceutically acceptable salts thereof; and the compound of Formula 1 or pharmaceutically acceptable salts thereof are for an antiplatelet therapy.